• Mashup Score: 0
    Looking Beyond the Typical Measures of MS Diagnosis - 3 year(s) ago

    A specific session at ECTRIMS 2021 showed the therapeutic advantages of incorporating patient-based metrics, says Dr Stephen Krieger.

    Source: Medscape
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of MedscapeNeuro
      MedscapeNeuro

      A specific session at #ECTRIMS2021 showed the therapeutic advantages of incorporating patient-based metrics, says Dr. Stephen Krieger. https://t.co/sp0KF3O7Qd https://t.co/qeJPqpQhXM

  • Mashup Score: 0
    Which agent is best for neuromyelitis optica? - 3 year(s) ago

    Researchers conducted an indirect treatment comparison on the efficacy of the three FDA-approved treatment options for adults with AQP4+ NMOSD.

    Source: www.mdedge.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of MDedgeNeurology
      MDedgeNeurology

      Read about the new indirect comparison of 3 new FDA approved treatment options for adults with AQP4+ neuromyelitis optica spectrum disorder. https://t.co/B3Xy1chPZk #ECTRIMS2021 https://t.co/VJIiwJB3fF

  • Mashup Score: 0
    Stem cell transplant benefits in secondary progressive MS - 3 year(s) ago

    The procedure was associated with a slowing of disability progression and a higher likelihood of disability improvement.

    Source: www.mdedge.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of MDedgeNeurology
      MDedgeNeurology

      An Italian study showed that autologous hematopoietic stem cell transplantation for the treatment of active secondary progressive MS is connected with better disability outcomes than other immunotherapies. https://t.co/sr5HRCgIJi #ECTRIMS2021 https://t.co/ZtHSSDqxs8

  • Mashup Score: 0
    Updated MS guidelines advocate earlier, more aggressive treatment - 3 year(s) ago

    The updated guidelines address the efficacy of disease-modifying therapies, early treatment decisions, disease/treatment response monitoring and treatment modifications, treatment suspension and disease reactivation, and pregnancy and breastfeeding.

    Source: www.mdedge.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of MDedgeNeurology
      MDedgeNeurology

      #ECTRIMS2021: Updated European guidelines recommend siponimod in progressive Multiple Sclerosis, as well as a general emphasis toward earlier and more aggressive treatment. https://t.co/Ox0Wnoflsh https://t.co/BZ45IZxgO7

Load More